Guy A. Young, MD

Professor of Pediatrics (Clinical Scholar)

Image of Guy A. Young, MD
Is this your profile? Click to edit

Overview

Following medical school, I completed my residency in pediatrics at Schneider Children’s Hospital-Long Island Jewish Medical Center which is part of the Albert Einstein College of Medicine. I then completed a fellowship in pediatric hematology/oncology at Children’s National Medical Center in Washington, DC which is part of the George Washington University School of Medicine. I then began my research career at the Children’s Hospital of Orange County under the mentorship of Dr. Diane Nugent. There, I became interested in improving the treatment for patients with hemophilia and inhibitors and for children with blood clots. I received my first independent grants there inculding a grant from the FDA to study a new anticoagulant in children. In addition, I became interested in thromboelastography. In 2007, I moved the Children’s Hospital Los Angeles where I am continuing to perform research in the same areas as I had started in Orange County.

Awards

  • National Hemophilia Foundation: Physician of the Year, 2013

Research Funding

  • Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in children
    NIH · R01HL095110 · Sep 26, 2008 – Jan 31, 2013 · Role: Principal Investigator
  • FONDAPARINUM IN CHILDREN WITH THROMBOSIS
    NIH · R01FD003091 · Sep 20, 2006 – May 31, 2009 · Role: Principal Investigator

Publications

  • Deconstructing gene therapy in hemophilia for the clinician. Hematology Am Soc Hematol Educ Program. 2025 12 05; 2025(1):659-667.. View in PubMed
  • Multisite Validation of a Venous Thrombosis Risk Model in Critically Ill Children Through the CHAT Consortium. Blood. 2025 Nov 24.. View in PubMed
  • Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. Blood. 2025 Jun 19; 145(25):2966-2977.. View in PubMed
  • Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy. Haemophilia. 2025 Jul; 31(4):799-806.. View in PubMed
  • Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice. Res Pract Thromb Haemost. 2025 May; 9(4):102926.. View in PubMed
  • Invitation and welcome to the 2025 ISTH Congress. J Thromb Haemost. 2025 May; 23(5):1461-1463.. View in PubMed
  • Reply to Letter to the Editor: “Deconstructing the ISTH Hemophilia Guidelines for the Clinician”: comment from Mancuso-ME et al. J Thromb Haemost. 2025 May; 23(5):1737-1738.. View in PubMed
  • Global Comparative Antithrombin Field Study: Impact of Laboratory Assay Variability on the Assessment of Antithrombin Activity Measurement at Fitusiran Clinical Decision-Making Points. Haemophilia. 2025 May; 31(3):566-574.. View in PubMed
  • Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial. Lancet Haematol. 2025 May; 12(5):e357-e364.. View in PubMed
  • Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials. Blood Vessel Thromb Hemost. 2025 Aug; 2(3):100069.. View in PubMed